October 01, 2024 The “Company” is proud to announce that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer’s and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study (“MHAS”) database.
The PREPARE Challenge, is sponsored by the National Institute on Aging (“NIA”), an institute of the National Institute of Health (“NIH”). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer’s and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC’s entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. “We are honored to win the two PREPARE prizes. These recognitions underscore IGC’s leadership in artificial intelligence (“AI”) and deep learning research aimed at improving Alzheimer’s disease prediction,” commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer’s exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda said: “We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer’s disease”.
About IGC Pharma S.A.S.
IGC Pharma SAS is at the forefront of integrating artificial intelligence (AI) into drug discovery, clinical research, and early disease detection. We are committed to revolutionizing the pharmaceutical landscape by leveraging AI-driven solutions to enhance Alzheimer’s disease (AD) research, biomarker identification, and patient diagnostics.
Our team of biomedical engineers, data scientists, and clinical researchers utilizes advanced AI models to accelerate drug development, optimize clinical trials, and improve early detection of neurodegenerative diseases. We apply cutting-edge deep learning techniques to analyze vast datasets, uncover novel therapeutic targets, and refine treatment strategies.
With a strong foundation in AI-powered analytics, IGC Pharma SAS is dedicated to pioneering the next generation of precision medicine, ensuring that breakthroughs in neuroscience and drug discovery translate into effective, accessible treatments for patients worldwide.
Join us in reshaping the future of healthcare through the power of AI.
